Log In
BCIQ
Print this Print this
 

Alere NMP22 BladderCheck

  Manage Alerts
Collapse Summary General Information
Company Alere Inc.
DescriptionEnzyme immunoassay which detects elevated levels of NMP22 protein for diagnosis and monitoring of bladder cancer
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose bladder cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$8,400.0M

$5,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2016

$8,400.0M

$5,800.0M

0

Get a free BioCentury trial today